Literature DB >> 1800379

Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity.

H Knothe1, P M Shah, O Eckardt.   

Abstract

The antimicrobial activity of cefpodoxime, the active metabolite of the new cephalosporin ester cefpodoxime proxetil, in comparison to cefixime, cefotiam, cefuroxime, and cefotaxime was determined against a broad spectrum of freshly isolated gram-positive and gram-negative bacterial strains. Cefpodoxime was demonstrated to be inhibitory at concentrations of less than or equal to 1 mg/l against 90% of strains of Moraxella catarrhalis, Haemophilus influenzae, Escherichia coli (beta-lactamase- negative strains), Klebsiella spp., Serratia spp., Proteus mirabilis, Proteus vulgaris, Providencia spp., and Salmonella spp. This antimicrobial activity of cefpodoxime was generally superior to that of cefuroxime and similar to that of cefixime. Cefpodoxime was active at less than or equal to 1 mg/l against 50% of the members of beta-lactamase-producing Escherichia coli, Enterobacter cloacae, Enterobacter aerogenes, Citrobacter spp., and Morganella morganii. Cefpodoxime proved to be highly inhibitory against group A, B, and G streptococci and Streptococcus pneumoniae (MIC90 less than 0.015 mg/l). The MICs of cefpodoxime and those of the other cephalosporins were less than 2 mg/l for greater than or equal to 90% of the strains of Staphylococcus aureus and Staphylococcus epidermidis, with the exception of cefixime which had no activity with MICs below 8 mg/l against these bacteria. Pseudomonas spp., Acinetobacter spp., and Enterococcus spp. were resistant to cefpodoxime. The antibacterial activity of cefpodoxime was only to a minor degree influenced by different growth conditions with the exception of high inoculum sizes against some beta-lactamase producing strains of gram-negative bacilli.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1800379     DOI: 10.1007/BF01645371

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  11 in total

1.  The in-vitro activity of cefpodoxime: a comparison with other oral cephalosporins.

Authors:  R Wise; J M Andrews; J P Ashby; D Thornber
Journal:  J Antimicrob Chemother       Date:  1990-04       Impact factor: 5.790

2.  In vitro activity of cefpodoxime, a new oral cephalosporin.

Authors:  E E Stobberingh; A W Houben; J H Philips
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

3.  In vitro activity of U-76,252 (CS-807), a new oral cephalosporin.

Authors:  R J Fass; V L Helsel
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

4.  In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin.

Authors:  Y Utsui; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

5.  In vitro activities and targets of three cephem antibiotics against Haemophilus influenzae.

Authors:  P M Mendelman; L L Henritzy; D O Chaffin; K Lent; A L Smith; T L Stull; E A Wiley
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

6.  Susceptibility of penicillin-sensitive and -resistant strains of Streptococcus pneumoniae to new antimicrobial agents, including daptomycin, teicoplanin, cefpodoxime and quinolones.

Authors:  P C Appelbaum; S K Spangler; E Crotty; M R Jacobs
Journal:  J Antimicrob Chemother       Date:  1989-04       Impact factor: 5.790

7.  In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

8.  Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807).

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

9.  Antibacterial activities of cefpodoxime, cefixime, and ceftriaxone.

Authors:  C C Knapp; J Sierra-Madero; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

10.  In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against clinical isolates of Branhamella catarrhalis.

Authors:  F A Sarubbi; A Verghese; C Caggiano; S Holtsclaw-Berk; S L Berk
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

View more
  4 in total

1.  Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors.

Authors:  Lisa M McGregor; Clinton F Stewart; Kristine R Crews; Michael Tagen; Amy Wozniak; Jianrong Wu; M Beth McCarville; Fariba Navid; Victor M Santana; Peter J Houghton; Wayne L Furman; Carlos Rodriguez-Galindo
Journal:  Pediatr Blood Cancer       Date:  2011-04-20       Impact factor: 3.167

Review 2.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

3.  In vitro activity of cefpodoxime in comparison with other oral beta-lactam antibiotics.

Authors:  F H Kayser
Journal:  Infection       Date:  1994 Sep-Oct       Impact factor: 3.553

Review 4.  Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  J E Frampton; R N Brogden; H D Langtry; M M Buckley
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.